文献速递乳腺外科

cN1 HR+/HER2-乳腺癌可触及淋巴结患者的前哨淋巴结活检:非随机临床试验

Sentinel Lymph Node Biopsy for Patients With cN1 HR+/HER2- Breast Cancer and Palpable Adenopathy: A Nonrandomized Clinical Trial.
PubMed 文献 · JAMA Surg · 2026-01-01

该非随机临床试验纳入78例经腋窝超声筛选的cN1 HR+/HER2-乳腺癌患者,评估 upfront 前哨淋巴结活检(SLNB)的可行性及腋窝淋巴结清扫(ALND)率。结果显示SLNB可行,仅24%患者接受ALND,中位随访25个月无孤立腋窝或局部区域复发。

要点

  • 腋窝超声筛选cN1 HR+/HER2-患者行 upfront SLNB 可行,ALND率24%。
  • 可触及的病变淋巴结在66.5%的实例中呈蓝色和/或放射性,需切除以降低假阴性率。
  • 中位随访25个月,无孤立腋窝或局部区域复发。

核心结论

  • 在经腋窝超声筛选的cN1 HR+/HER2-乳腺癌患者中,upfront SLNB可行,且可安全地省略ALND。

研究设计与样本

  • 非随机临床试验,纳入78例cTx/cT1-2 cN1 HR+/HER2-且腋窝超声显示3个或以下形态异常淋巴结的乳腺癌患者,来自4个中心。

主要发现

  • 78例患者中,24例(31%)有1个阳性前哨淋巴结,30例(38%)有2个,24例(31%)有3个或以上。
  • 59例(76%)仅行SLNB,19例(24%)行ALND,其中5例为有指征的ALND被推迟。
  • 在随访12个月或以上(n=68;中位25个月)的患者中,无孤立腋窝或局部区域复发。
  • 可触及的病变淋巴结在161次实例中107次(66.5%)呈蓝色和/或放射性。

关键数值与推荐

  • SLNB采用单/双示踪剂定位,68例(87%)使用双示踪剂,75例(96%)获取3个或以上前哨淋巴结。
  • ALND指征为3个或以上阳性前哨淋巴结。

临床怎么用

  • 对cN1 HR+/HER2-乳腺癌患者,可考虑先行腋窝超声筛选,对形态异常淋巴结≤3个者行 upfront SLNB。
  • SLNB时应切除可触及的病变淋巴结以降低假阴性率,从而可能安全地省略ALND。

局限性

  • 非随机设计,样本量较小(78例),随访时间有限(中位25个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Randomized trials established the safety of omitting axillary lymph node dissection (ALND) among patients with clinically node-negative breast cancer and less than 3 positive sentinel lymph nodes (+SLNs) having upfront surgery and adjuvant radiation. Patients with palpable mobile level I/II axillary adenopathy (cN1) were not eligible for these studies. Presently, more than 80% of patients with HR+/HER2- cN1 disease undergo ALND either at upfront surgery or after neoadjuvant therapy, despite evidence that 50% to 60% will have only 1 or 2 positive nodes. OBJECTIVE: To determine upfront sentinel lymph node biopsy (SLNB) feasibility and evaluate ALND rate among patients with HR+/HER2- cN1 breast cancer selected with axillary ultrasound (AUS). DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized clinical trial involved patients with cTx/cT1-2 cN1 HR+/HER2- breast cancer with 3 or fewer morphologically abnormal nodes on AUS at 4 centers. The trial began on April 20, 2021, and the database for this report was frozen on September 26, 2024. INTERVENTIONS: Patients underwent upfront lumpectomy/mastectomy and SLNB, with single/dual-tracer mapping. ALND was indicated for 3 or more positive SLNs. MAIN OUTCOMES AND MEASURES: The primary outcome was ALND rate. Secondary outcomes were frequency of palpable nodes being radioactive/blue and locoregional recurrence. RESULTS: Among 78 enrolled patients, the median (IQR) age was 58 (49.0-66.5) years. Most tumors were cT1 (37 [47%]) or cT2 (40 [51%]), 56 patients (72%) had ductal histology, and 59 tumors (76%) were moderately differentiated. On AUS, 39 patients (50%) had 1 abnormal-appearing node, 33 (42%) had 2, and 6 (8%) had 3. Median (IQR) pathologic tumor size was 2.3 (1.6-3.3) cm, 50 patients (64%) had lymphovascular invasion, and 54 (69%) had extracapsular extension. SLNB was performed with dual tracer in 68 (87%), and 3 or more SLNs were retrieved in 75 (96%). The palpable diseased nodes were blue and/or radioactive in 107 of 161 instances (66.5%). Overall, 24 patients (31%) had 1 +SLN, 30 patients (38%) had 2 +SLNs, and 24 patients (31%) had 3 or more +SLNs. SLNB alone was performed in 59 patients (76%), while 19 (24%) had ALND; indicated ALND was deferred in 5 cases. Among those with 12 months or more follow-up (n = 68; median, 25 months), there have been no isolated axillary or locoregional recurrences. CONCLUSIONS AND RELEVANCE: This study found that SLNB is feasible among patients with cN1 HR+/HER2- disease and that resection of palpable nodes is necessary to minimize false-negative rates. This approach affords the opportunity to omit ALND and minimize morbidity among patients with cN1 cancer and limited nodal burden. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04854005.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Mamtani A, Pilewskie M, Wilson N, et al. Sentinel Lymph Node Biopsy for Patients With cN1 HR+/HER2- Breast Cancer and Palpable Adenopathy: A Nonrandomized Clinical Trial. JAMA Surg. 2026. PMID: 42090164. doi:10.1001/jamasurg.2026.1268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。